Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of California, Los Angeles Centers for Disease Control and Prevention |
---|---|
Information provided by: | University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT00453700 |
Chagas disease is endemic to the Americas, infecting between 16-18 million individuals. In immigrant populations in the United States from endemic areas, it is estimated up to 4.9% may be asymptomatic carriers of Trypanosoma cruzi, the organism which causes Chagas disease. Between 10-20% of these patients progress to development of end-stage cardiomyopathy with a high associated morbidity. Following acute disease, patients enter into an indeterminate phase which can last 10-20 years. The earliest sign of cardiac involvement usually is electrocardiogram abnormalities. The most common abnormality is right bundle branch block (RBBB), followed by left anterior fascicular block (LAFB), and left bundle branch block (LBBB). Recent studies have shown that treatment of patients at this stage with antiparasitics may delay the progression of overt cardiomyopathy.
At the University of California, Los Angeles, there is a large population of immigrant patients from countries endemic to Chagas disease. The researchers propose that screening patients with conduction abnormalities on electrocardiogram may be a potentially useful method to identify patients with early cardiac manifestations of Chagas disease. The researchers hope to enroll approximately 300 individuals with RBBB, LAFB or LBBB on electrocardiogram to determine the incidence of Chagas disease in this patient population.
Condition | Intervention |
---|---|
Chagas Disease |
Procedure: Trypanosoma cruzi serology |
Study Type: | Interventional |
Study Design: | Screening, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
One of the following EKG abnormalities:
Exclusion Criteria:
Contact: Sheba K Meymandi, M.D. | 818-364-4289 | smeymandi@ladhs.org |
Contact: Mahmoud I Traina, M.D. | 818-364-4287 | mitraina@gmail.com |
United States, California | |
OV-UCLA Medical Center | Recruiting |
Sylmar, California, United States, 91342 |
Principal Investigator: | Sheba K Meymandi, M.D. | OV-UCLA Medical Center |
Study ID Numbers: | 06H-561004 |
Study First Received: | March 28, 2007 |
Last Updated: | March 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00453700 History of Changes |
Health Authority: | United States: Institutional Review Board |
chagas trypanosoma cruzi |
Protozoan Infections Trypanosomiasis Parasitic Diseases Chagas Disease Congenital Abnormalities |
Protozoan Infections Trypanosomiasis Parasitic Diseases |
Sarcomastigophora Infections Mastigophora Infections Chagas Disease |